TY - JOUR
T1 - Emerging Predictors by Non-HDL-C/HDL-C Ratio and Novel Biomarkers for Coronary Slow Flow Phenomenon
AU - Vairaperumal, Tharmaraj
AU - Tsai, Zong Yun
AU - Liu, Ping Yen
N1 - Publisher Copyright:
© 2024, Republic of China Society of Cardiology. All rights reserved.
PY - 2024/7
Y1 - 2024/7
N2 - The coronary slow-flow (CSF) phenomenon is a condition characterized by delayed coronary opacification during diagnostic angiography without the presence of epicardial coronary artery disease. This mini-review explores various emerging predictors and biomarkers associated with CSF, aiming to address the potential diagnostic tools. A comprehensive analysis of recent studies has investigated different biomarkers, including growth differentiation factor 15, galectin 3, microRNA (miRNA)-22, miRNA-155, interleukin 34, soluble vascular cell adhesion molecule-1, long non-coding RNA, plasma choline, adropin, and lipid markers nonhigh-density lipoprotein cholesterol (HDL-C)/HDL-C ratio to enhance understanding and predict CSF. Additionally, we have summarizes the major findings and significant limitations observed in various studies on CSF biomarkers. The implications of these findings suggest significant advancements in personalized treatment strategies and improved prognostic outcomes for patients exhibiting CSF.
AB - The coronary slow-flow (CSF) phenomenon is a condition characterized by delayed coronary opacification during diagnostic angiography without the presence of epicardial coronary artery disease. This mini-review explores various emerging predictors and biomarkers associated with CSF, aiming to address the potential diagnostic tools. A comprehensive analysis of recent studies has investigated different biomarkers, including growth differentiation factor 15, galectin 3, microRNA (miRNA)-22, miRNA-155, interleukin 34, soluble vascular cell adhesion molecule-1, long non-coding RNA, plasma choline, adropin, and lipid markers nonhigh-density lipoprotein cholesterol (HDL-C)/HDL-C ratio to enhance understanding and predict CSF. Additionally, we have summarizes the major findings and significant limitations observed in various studies on CSF biomarkers. The implications of these findings suggest significant advancements in personalized treatment strategies and improved prognostic outcomes for patients exhibiting CSF.
UR - http://www.scopus.com/inward/record.url?scp=85200661272&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85200661272&partnerID=8YFLogxK
U2 - 10.6515/ACS.202407_40(4).20240624A
DO - 10.6515/ACS.202407_40(4).20240624A
M3 - Review article
AN - SCOPUS:85200661272
SN - 1011-6842
VL - 40
SP - 367
EP - 372
JO - Acta Cardiologica Sinica
JF - Acta Cardiologica Sinica
IS - 4
ER -